GSK to launch appeal following Zantac setback

GSK is expected to soon begin formal proceedings to appeal a recent major setback in its costly legal battle over Zantac.

Shares of GSK, one of Britain’s largest pharmaceutical companies, fell sharply last week after a Delaware state court judge ruled that experts could testify on behalf of just under of 70,000 plaintiffs who claimed the former blockbuster heartburn treatment gave them cancer.

GSK said it disagreed with the decision and is now expected to file an appeal with the Delaware Supreme Court.

The company expects that an appeal, if granted, could take between eight months and a year.

The lengthy litigation, which first angered investors in August 2022, created